Studying heart inflammation from immunotherapy in lung cancer
Part of Cancer, Heart & circulation, Lungs & breathing clinical trials.
This study looks for specific markers in the blood that can help doctors better understand and treat heart inflammation (myocarditis) caused by immunotherapy in people with lung cancer. If you join, you will help find ways to improve care for other patients.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have lung cancer and have been treated with immunotherapy (one dose or more).
- Your doctor has diagnosed you with immunotherapy-related heart inflammation (myocarditis).
- You are at least 18 years old.
- You are not pregnant or breastfeeding.
- You do not have other serious heart conditions (like a recent heart attack or severe irregular heartbeat).
- You do not have another cancer, an immune-suppressing condition, or an autoimmune disease.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study monitors how the heart and lungs respond to radiation therapy combined with immunotherapy for locally advanced lung cancer. It aims to learn how well patients tolerate treatment and to detect early signs of side effects.
This study looks at genetic (DNA) information to find a marker that can help predict whether immunotherapy will work for lung cancer. If you’ve already received an immune checkpoint inhibitor, your tumor/genetic data may be analyzed to look for clues that guide treatment.
This research tracks outcomes for cancer patients who developed heart inflammation (myocarditis) while receiving immune checkpoint inhibitor therapy. By studying survival patterns, researchers hope to better understand how to manage this serious side effect and improve care for future patients.
This study looks at genetic factors that may affect the risk of heart inflammation (myocarditis) caused by immune checkpoint inhibitors (ICIs), a type of cancer immunotherapy. It aims to find out if your genes make you more likely to develop this side effect.
This study looks for signs in the blood that can tell if a lung cancer patient is developing a side effect called pneumonitis (lung inflammation) from checkpoint inhibitor treatment. It may help doctors catch and treat this side effect early.
This trial studies whether immunotherapy drugs (called immune checkpoint inhibitors) affect the small blood vessels of the heart. If you have breast cancer or lung cancer and are starting a specific treatment plan, you may be asked to have a special heart scan before and during therapy.
Hear when a new Lung cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.